Dr. Lyon discusses risk of VTE following radical cystectomy
“Clinicians should do whatever they're able to try to limit or reduce the need for an intraoperative transfusion,” says Timothy D. Lyon, MD, FACS.
In this interview, Timothy D. Lyon, MD, FACS, discusses his recent study, “Intraoperative blood transfusion is associated with increased risk of venous thromboembolism after radical cystectomy.” Lyon is a practicing urologic oncologist at Mayo Clinic in Jacksonville, Florida.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
